PUBMEDCENTRAL.NIH.GOV : www.pubmedcentral.nih.gov - 4 in TOP 100 MEDICAL SITES. Rating: 800000.

Description: PubMed Central is an archive of life sciences journal literature that is developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).

Most popular searches: www.pubmedcentral.ni.gov, wwwpubmedcentral.nih.gov, www.ubmedcentral.nih.gov, www.pubmedcentralnih.gov, www.pubmedcentral.ih.gov, www.pubmedcentral.nih.ov, www.pubmecentral.nih.gov, www.pubmdcentral.nih.gov, national institutes of health, wwwpubmedcentral.nih.gov, national library of medicine, database, www.pubmedcental.nih.gov, pubmed, ncbi, ww.pubmedcentral.nih.gov, digital archive, www.pubmedcenral.nih.gov, free journals, www.pubedcentral.nih.gov, free full text, www.pubmedcentral.nih.com, biomedicine, www.pubmedcentral.nih.gv, national center for biotechnology information, www.pbmedcentral.nih.gov, ww.pubmedcentral.nih.gov, bioinformatics, www.pumedcentral.nih.gov, www.pubmedcentra.nih.gov, nih, nlm, archive, digitization, www.pubmedcntral.nih.gov, www.pubmedentral.nih.gov, back issue, pubmed central, bookshelf, PMC, scanning, www.pubmedcentral.nih.go, www.pubmedcentral.nh.gov, www.pubmedcentral.nihgov, www.pubmedcetral.nih.gov, www.pubmedcentrl.nih.gov, www.pubmedcentral.nih.gov

WFU Baptist among safety initiative leaders
Wake Forest University Baptist Medical Center is one of the first health systems in the country to join a national effort examining ways to cut down on hospital-acquired infections.
feeds.bizjournals.com

Genzyme Fails to Receive Approval for Leukemia Drug
Zacks.com submits: On Wednesday, Genzyme Corp. (GENZ) failed to receive U.S. Food and Drug Administration (FDA) approval for Clolar in elderly adults with acute myeloid leukemia (AML). Clolar is currently approved for pediatric acute lymphoblasic leukemia (ALL) patients who have relapsed or refractory disease after at least two prior regimens. Genzyme was looking to get Clolar approved for the treatment of previously untreated adults aged 60 or older with AML, who have at least one unfavorable prognostic risk factor. Complete Story »
seekingalpha.com

Court Rejects Drug-Patent Challenge
The Supreme Court Monday rejected a generic-drug maker's appeal challenging a patent for a blood-thinning drug developed by Sanofi-Aventis.
online.barrons.com

GoodBelly Probiotic Fruit Drink - Video
Makers of GoodBelly Probiotic Fruit Drink Create Video to Educate on Benefits of Probiotics to Keep Digestive Health in Balance, and Strengthen Immune System
feedproxy.google.com

Neostem: Ready to Take Off?
M.E. Garza submits: This morning's news release by NeoStem (NBS) is a peek into the metamorphasis we learned would be taking place at the company last week.During our exclusive interview with Robin L. Smith M.D., Chairman of the Board and Chief Executive Officer of NeoStem Inc., last week, she shared a few promising glimpses about the company's future. But some of the revelations we found after digging through some of the company's recent filings really start to put things into focus more clearly after today's announcement.Complete Story »
seekingalpha.com